New developments in the pharmacologic treatment of schizoaffective disorder

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 9, 1996, Pages 41-48

  Keck Jr , Paul E ^a   McElroy, Susan L ^a   Strakowski, Stephen M ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CLOZAPINE; LITHIUM; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; VALPROIC ACID;

ANTICONVULSANT THERAPY; CONFERENCE PAPER; DEPRESSION; LIGAND BINDING; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL; PROPHYLAXIS; RECEPTOR BLOCKING; SCHIZOIDISM;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CARBAMAZEPINE; CLINICAL TRIALS; CLOZAPINE; DRUG THERAPY, COMBINATION; HUMANS; PSYCHOTIC DISORDERS; RECEPTORS, SEROTONIN; RISPERIDONE; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 10144227769     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (78)

1. Keck PE Jr, McElroy SL, Strakowski SM, et al. Pharmacologic treatment of schizoaffective disorder. Psychopharmacology (Berl) 1994;114:529-538
2. Janicak PG, Davis JM, Preskorn SH, et al. Principles and Practice of Psychopharmacotherapy. Baltimore, Md: Williams & Wilkins; 1993
3. Jefferson JW, Griest JH. Mood disorders. In: Hales RE, Yudofsky SC, Talbott JA, eds. Textbook of Psychiatry. 2nd ed. Washington, DC: American Psychiatric Press; 1994:465-494
4. Maj M. Evolution of the American concept of schizoaffective psychosis. Neuropsychobiology 1984;11:7-13
5. Brockington IF, Reper A, Copas J, et al. Schizophrenia, bipolar disorder and depression: a discriminant analysis, using "lifetime" psychopalhology ratings. Br J Psychiatry 1991;159:485-494
6. Maier W, Lichterman D, Minges J, et al. Schizoaffective disorder and affective disorders with mood-incongruent psychotic features: keep separate or combine? evidence from a family study. Am J Psychiatry 1992;149: 1666-1673
7. Robins LN, Heizer JE, Weismann MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984;41:949-958
8. Lee CK, Kwak YS, Rhee H, et al. The nationwide epidemiological study of mental disorders in Korea. J Korean Med Sci 1987;2:19-34
9. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
12. Feighner JP, Robins E, Guze SB, et al. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 1972;26:57-63
13. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 1978;35:773-782
14. Williams JBW, Gibbon M, First MB, et al. The structured clinical interview for DSM-III-R (SClD), II: multisite test-retest reliability. Arch Gen Psychiatry 1992;49:630-636
15. Malhotra AK, Litman RE, Su TP, et al. Clozapine response in schizoaffective disorder. In: New Research Program and Abstracts of the 146th Annual Meeting of the American Psychiatric Association; May 24, 1993; San Francisco, Calif. Abstract NR53:73
16. Linström LH. A retrospective study of the long-term efficacy and safety of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period. Psychopharmacology (Berl) 1989;99(suppl):84-86
17. Naber D, Hippius H. The European experience with use of clozapine. Hosp Community Psychiatry 1990;41:886-890
18. Stefanowicz P. Initial results of clozapine and lithium carbonate treatment of manic syndromes in the course of schizoaffective psychosis. Psychiatr Pol 1990;24:27-30
19. McElroy SL, Dessain EC, Pope HG Jr, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J CHn Psychiatry 1991;52:411-414
20. Banov MD, Zarate CA, Tohen M, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994;55:295-300
21. Hillert A, Maier W, Wetzel H, et al. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome: a functional approach. Pharmacopsychiatry 1992;25:213-217
22. Dwight MM, Keck PE Jr, Stanton SP, et al. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder [letter]. Lancet 1994;344:554-555
23. Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993;26:121-124
24. Keck PE Jr, Wilson DR, Strakowski SM, et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 1995;56:466-470
25. Johnson G, Gershon S, Hekiman LJ. Controlled evaluation of lithium and chlorpromazine in the treatment of manic stales: an interim report. Compr Psychiatry 1968;9:563-573
26. Johnson G, Gershon S, Burdock EI, et al. Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. Br J Psychiatry 1971;119:267-276
27. Shopsin B, Kim SS, Gerson S. A controlled study of lithium vs chlorpromazine in acute schizophrenics. Br J Psychiatry 1971;119:435-440
28. Prien RF, Point P, Caffey EM, et al. A comparison of lithium carbonate and chlorpromazine in the treatment of excited schizoaffectives. Arch Gen Psychiatry 1972;27:182-189
29. Small JG, Kellams JJ, Milstein V, et al. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 1975;132:1315-1317
30. Brockington IF, Kendall RE, Kellett JM, et al. Trials of lithium, chlorpromazine and amitriptyline in schizoaffective patients. Br J Psychiatry 1978; 133:162-168
31. Biederman J, Lerner Y, Belmaker RH. Combination of lithium carbonate and haloperidol in schizoaffective disorder. Arch Gen Psychiatry 1979;36: 327-333
32. Alexander PE, Van Kammen DP, Bunney WE. Antipsychotic effects of lithium in schizophrenia. Am J Psychiatry 1979;136:282-287
33. Growe GA, Crayton JW, Klass DB, et al. Lithium in chronic schizophrenia. Am J Psychiatry 1979;136:454-455
34. Prusoff BA, Williams DH, Weismann MM, et al. Treatment of secondary depression in schizophrenia: a double-blind, placebo-controlled study of amitriptyline added to perphenazine. Arch Gen Psychiatry 1979;36: 569-575
35. Bigelow LB, Weinberger DR, Wyatt RJ. Synergism of combined lithium-neuroleptic therapy: a double-blind, placebo-controlled case study. Am J Psychiatry 1981;138:81-83
36. Carman JS, Bigelow LB, Wyatt RJ. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 1981; 42:124-128
37. Braden W, Fink EB, Qualls CB, et al. Lithium and chlorpromazine in psychotic inpatients. Psychiatry Res 1982;7:69-81
38. Goodnick PJ, Meltzer HY. Treatment of schizoaffective disorders. Schizophr Bull 1984;10:30-48
39. Levitt JJ, Tsuang MT. The heterogeneity of schizoaffective disorder: implications for treatment. Am J Psychiatry 1988;145:926-936
40. Lapenseé MA. A review of schizoaffective disorder, II: somatic treatment. Can J Psychiatry 1992;37:347-349
41. Angst J, Dittrich A, Grof P. The course of endogenous affective psychosis and its modification by prophylactic treatment. International Pharmacopsychiatry 1969;2:1-11
42. Prien RF, Caffey EM, Klett CJ. Factors associated with treatment success in lithium carbonate prophylaxis. Arch Gen Psychiatry 1974;31:189-192
43. Mattes JA, Nayak D. Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizoaffectives. Biol Psychiatry 1984;19:445-449
44. Sins SG. The treatment of schizoaffective disorder. In: Dunner DL, ed. Current Psychiatric Therapy. Philadelphia, Pa: WB Saunders; 1993:160-165
45. Keck PE Jr, McElroy SL, Nemeroff CB. Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatty Clin Neurosci 1992;4:395-405
46. Simhandl C, Meszaros K. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review. J Psychiatry Neurosci 1992;17:1-14
47. McElroy SL, Keck PE Jr. Treatment guidelines for valproate in bipolar and schizoaffective disorders. Can J Psychiatry 1993;38(suppl 2):62-66
48. Okuma T, Yamashita I, Takahashi R, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoafieclive disorders. Acta Psychiatr Scand 1989;80:250-259
49. Placidi GF, Lenzi A, Lazzerini F, et al. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry 1986;47:490-494
50. Meltzer HY. The mechanism of action of clozapine in relation to its clinical advantages. In: Meltzer HY, ed. Novel Antipsychotic Drugs. New York, NY: Raven Press; 1991:1-13
51. Calabrese JR, Meltzer HY, Markovitz PJ. Clozapine prophylaxis in rapid cycling bipolar disorder [letter]. J Clin Psychopharmacol 1991;11:396-397
52. Parsa MA, Ramirez LF, Loula EC, et al. Effect of clozapine on psychotic depression and parkinsonism [letter]. J Clin Psychopharmacol 1991;11: 330-331
53. Privitera MR, Lamberti JS, Maharaj K. Clozapine in a bipolar depressed patient [letter]. Am J Psychiatry 1993;150:986
54. Suppes T, McElroy SL, Gilbert J, et al. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992;32:270-280
55. Cole JO, Banov MD, Green A, et al. Clozapine in the treatment of refractory acute bipolar mania. In: New Research Program and Abstracts of the 146th Annual Meeting of the American Psychiatric Association; May 26, 1993; San Francisco, Calif. Abstract NR455:174
56. Frankenburg FR. Clozapine and bipolar disorder [letter]. J Clin Psychopharmacol 1993;13:289-290
57. Suppes T, Phillips KA, Judd CR. Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: a report of three cases. Biol Psychiatry 1994; 36:338-340
58. Singh AN, Catalan J. Risperidone in HIV-related manic psychosis [letter]. Lancet 1994;344:1029-1030
59. Goodnick PJ. Risperidone treatment of refractory acute mania [letter]. J Clin Psychiatry 1995;56:431-432
60. Borison RL, Pathiraja AP, Diamond BI, et al. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-218
61. 3H]spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exp Ther 1980;215:582-587
62. Blackshear MA, Sanders-Bush E. Serotonin receptor sensitivity after acute and chronic treatment with mianserin. J Pharmacol Exp Ther 1982;221: 303-308
63. 3H-ketanserin recognition sites. Life Sci 1984;36:713-721
64. 2 receptor antagonist (LY53857). Biol Psychiatry 1984;20:592-597
65. 2 receptor blocker. Drug Development and Research 1986;8:205-211
66. 2 receptor binding on blood platelets: a peripheral marker for depression? Life Sci 1987;41: 2485-2492
67. 3H-LSD) in the blood platelets of depressed patients. Life Sci 1989;44:725-734
68. Pandey GN, Pandey SC, Janicak PG, et al. Platelet serotonin-2 receptor binding sites in depression and suicide. Biol Psychiatry 1990;28:215-222
69. 2 receptor changes in major depression. Biol Psychiatry 1990;27:489-496
70. Meltzer HY, Umberkoman-Wiita B, Robertson A, et al. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. Arch Gen Psychiatry 1984;41:366-374
71. Maes M, De Ruyter M, Claes R, et al. The Cortisol response to 5-hydroxytryptophan, orally, in depressive inpatients. J Affect Disord 1989; 13:23-30
72. Aprison MH, Takahaski R, Tachiki K. Hypersensitive serotonergic receptors involved in clinical depression: a theory. In: Haber B, Aprison MH, eds. Neuropharmacology and Behavior. New York, NY: Plenum; 1978:23-48
73. Barnes TRE, Curson DA, Liddle PF, et al. The nature and prevalence of depression in chronic schizophrenic inpatients. Br J Psychiatry 1989;154: 486-491
74. Kulhara P, Avasthi A, Chadda R, et al. Negative and depressive symptoms in schizophrenia. Br J Psychiatry 1989;154:207-211
75. Newcomer JW, Faustman WO, Yeh W, et al. Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia. Psychiatry Res 1989;31:243-250
76. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;51:805-835
77. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989;99:S18-S27
78. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology (Berl) 1989;93:45-50